CURRENT OPINION IN ONCOLOGY

简称 CURR OPIN ONCOL ·UNITED STATES ·出版周期 Bimonthly ·年均收录 70 篇

2.4

最新影响因子

1.40%

自引率

一般

投稿难度

偏慢,4-8周

审稿周期

期刊简介

CURRENT OPINION IN ONCOLOGY是一本国际知名的肿瘤学杂志，ISSN号为1040-8746，由美国出版商Lippincott Williams & Wilkins出版，出版地为美国，出版周期为双月刊。该杂志的影响因子较高，具体数值因年份不同而有所变化，属于SCI收录期刊，中科院分区通常位于医学大类2区或3区，为非开放获取（非OA）期刊。杂志的发文特点侧重于肿瘤学领域的最新研究进展和综述文章，涵盖肿瘤生物学、临床肿瘤学、治疗策略、流行病学等多个研究方向，尤其注重专家观点和前沿综述。杂志的质量较高，因其严格的同行评审和权威性内容而受到学术界认可，但投稿难度较大，竞争激烈，且非OA模式可能导致读者获取全文受限。总体而言，该杂志是肿瘤学领域的重要参考期刊，适合高水平的学术研究和临床实践参考。

影响因子趋势

近期发表

Precision medicine for pediatric gliomas 2026-09-19

Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2-mutated and PALB2-mutated breast cancers 2026-09-19

Neurotoxicity and cognitive outcomes in modern therapies for primary central nervous system lymphoma 2026-09-18

Safety management of anti TROP2 ADCs in patients with breast cancer 2026-09-18

The evolving role of nuclear medicine in differentiating pseudoprogression from tumor progression in gliomas 2026-09-18

Emerging role of targeted therapy in drug-resistant epilepsy in patients with glioma 2026-09-18

The next-generation biomarkers in early-stage triple negative breast cancer 2026-09-17

Paraneoplastic neurological syndromes: an update on incidence, antibody discovery, and testing 2026-09-08

Implementing liquid biopsy in HR+/HER2− metastatic breast cancer: challenges and opportunities 2026-09-03

Antibody–drug conjugates in breast cancer: the first-line and curative setting 2026-08-14